Danaher 's (NYSE: DHR) mix of life sciences and diagnostic businesses made it one of the big winners from the pandemic. Its status as one of the go-to options for investors looking for portfolio protection from a resurgence of the pandemic has never been in doubt. Its life sciences tools help medical bodies research vaccines and therapies (including COVID-19), and its diagnostics tools test for medical conditions, including COVID-19.
The key question is just what kind of growth rate can investors expect in the future, and does the company's valuation justify its long-term growth trajectory?
Image source: Getty Images.
For further details see:
Down 25% in 2022: Buy This High-Quality Stock on a Dip?